H2BC9

Across TCGA pan-cancer cohorts, H2BC9 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated H2BC9 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher H2BC9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated H2BC9 expression acts as an unfavorable survival marker.

OV and ESCA are the cancer types where H2BC9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.221	0.542	.025	18	view →
ESCA	OS	Median	III,IV	0.124	0.574	.004	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

H2BC9–OV (DFS)

Open the OV breakdown →